Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.
New therapies are needed for metastatic breast cancer patients.Oncolytic herpes simplex virus (oHSV) is an exciting 3 nef runes therapy being developed for use against aggressive tumors and established metastases.Although oHSV have been demonstrated safe in clinical trials, a lack of sufficient potency has slowed the clinical application of this ap